Olivier Michel1, Robert Murdoch, Alfred Bernard. 1. Clinics of Allergology and Respiratory Diseases, Saint-Pierre University Hospital, Free University of Brussels, Rue Haute 322, B-1000 Brussels, Belgium. omichel@ulb.ac.be
Abstract
BACKGROUND: Animal models of lung inflammation have validated the plasma 16-kd Clara cell protein (CC16) as a peripheral marker of the permeability of the alveolocapillary barrier. OBJECTIVE: We investigated in human beings whether inhaled LPS induced a rise in airways permeability measured by the plasma changes in CC16. METHODS: The CC16 was measured in plasma from 15 subjects exposed to LPS by inhalation, during which the kinetics and the dose-response relationship of LPS-induced CC16 were evaluated. Because LPS-induced response involves macrophages activation, the protective effect of oral methylprednisolone was also evaluated. RESULTS: An inhalation of 50 microg LPS induced a significant ( P < .001) rise in CC16 after 6 hours (from 7.24 [+/-0.68] microg/L to 10.69 [+/-0.99] microg/L) that normalized at 24 hours (6.65 [+/-0.33] microg/L). The CC16 response was dose-related, with the no-response threshold 0.5 microg LPS. A 6-day treatment with 20 mg/d methylprednisolone inhibited significantly ( P < .001) the CC16 response to 50 microg LPS. CONCLUSION: Exposure to LPS by inhalation in healthy subjects induces an intravascular leakage of CC16 that can be blocked by corticosteroids. These observations further validate plasma CC16 as a noninvasive test of the alveolocapillary barrier permeability.
BACKGROUND: Animal models of lung inflammation have validated the plasma 16-kd Clara cell protein (CC16) as a peripheral marker of the permeability of the alveolocapillary barrier. OBJECTIVE: We investigated in human beings whether inhaled LPS induced a rise in airways permeability measured by the plasma changes in CC16. METHODS: The CC16 was measured in plasma from 15 subjects exposed to LPS by inhalation, during which the kinetics and the dose-response relationship of LPS-induced CC16 were evaluated. Because LPS-induced response involves macrophages activation, the protective effect of oral methylprednisolone was also evaluated. RESULTS: An inhalation of 50 microg LPS induced a significant ( P < .001) rise in CC16 after 6 hours (from 7.24 [+/-0.68] microg/L to 10.69 [+/-0.99] microg/L) that normalized at 24 hours (6.65 [+/-0.33] microg/L). The CC16 response was dose-related, with the no-response threshold 0.5 microg LPS. A 6-day treatment with 20 mg/d methylprednisolone inhibited significantly ( P < .001) the CC16 response to 50 microg LPS. CONCLUSION: Exposure to LPS by inhalation in healthy subjects induces an intravascular leakage of CC16 that can be blocked by corticosteroids. These observations further validate plasma CC16 as a noninvasive test of the alveolocapillary barrier permeability.
Authors: Raminder Aul; Jane Armstrong; Annelyse Duvoix; David Lomas; Brian Hayes; Bruce E Miller; Chris Jagger; Dave Singh Journal: Br J Clin Pharmacol Date: 2012-12 Impact factor: 4.335
Authors: Christian Rosas-Salazar; Tebeb Gebretsadik; Kecia N Carroll; Sara Reiss; Nancy Wickersham; Emma K Larkin; Kristina M James; E Kathryn Miller; Larry J Anderson; Tina V Hartert Journal: Pediatr Allergy Immunol Pulmonol Date: 2015-09-01 Impact factor: 1.349
Authors: R Daneshzadeh Tabrizi; A Bernard; A M Thommen; F De Winter; A Oppliger; S Hilfiker; A Tschopp; P Hotz Journal: Int Arch Occup Environ Health Date: 2010-03-11 Impact factor: 3.015
Authors: Ana Fernandez-Bustamante; Jelena Klawitter; John E Repine; Amanda Agazio; Allison J Janocha; Chirag Shah; Marc Moss; Ivor S Douglas; Zung Vu Tran; Serpil C Erzurum; Uwe Christians; Tamas Seres Journal: Anesthesiology Date: 2014-09 Impact factor: 7.892
Authors: Rogier M Determann; Julian L Millo; Sam Waddy; Rene Lutter; Chris S Garrard; Marcus J Schultz Journal: BMC Pulm Med Date: 2009-12-03 Impact factor: 3.317